Sarbecovirus

Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model

Retrieved on: 
Wednesday, August 4, 2021
Coronaviridae, Sarbecovirus, Zoonoses, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome, Variants of SARS-CoV-2

Based on this screening effort, the most efficacious derivative (Salicyn-30) was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection.

Key Points: 
  • Based on this screening effort, the most efficacious derivative (Salicyn-30) was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection.
  • This analysis demonstrated that Salicyn-30 can potentially reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in COVID-19 infections.
  • Moreover, based on their mechanism of action, Salicyn-30 and other lead compounds may be equally effective against recent emerging SARS-CoV-2 variants.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology

Retrieved on: 
Tuesday, August 3, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Ondine

Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.

Key Points: 
  • Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many pathogens including MRSA, Candida auris and SARS-Cov-2.
  • Dr. Nicolas Loebel, Ondine Biomedicals President and Chief Technology Officer, will present the results in the Photomedicine and SARS-CoV-2/ASP-ESP Symposium.
  • Ondine Biomedical Inc. is a Canadian headquartered, medical device company led by Founder and CEO, Carolyn Cross.

Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research

Retrieved on: 
Monday, August 2, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Brilacidin, Variants of SARS-CoV-2, Severe acute respiratory syndrome coronavirus, COVID-19, Antiviral drug, Severe acute respiratory syndrome

WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Companys defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.

Key Points: 
  • WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Companys defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.
  • Brilacidin SARS-CoV-2 Manuscript: Scientists conducting laboratory testing of Brilacidin, in particular its ability to block entry of SARS-CoV-2 into human cells, have submitted their research findings for peer-review publication.
  • These data include insights into Brilacidins antiviral mechanisms of action and Brilacidin activity against the Alpha (B.1.1.7) and Gamma (P.1) SARS-CoV-2 variants.
  • Taken together, the results from ongoing lab research into Brilacidins antiviral properties by different groups of scientists only strengthens our belief in Brilacidin, said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, 3C-like protease, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Beta variant, SARS-CoV-2 Delta variant, Middle East respiratory syndrome–related coronavirus, COVID-20

BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

Key Points: 
  • BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.
  • Cocrystal previously announced that CDI-45205 and analogs exhibited broad-spectrum activity against the SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the Wuhan strain.
  • The broad-spectrum activity against these SARS-CoV-2 variants is highly encouraging as CDI-45205 previously demonstrated excellent in vivo efficacy in a MERS-CoV-2 infected animal model.
  • The Company continues to develop SARS-CoV-2 oral protease inhibitors and replication inhibitors using its proprietary drug discovery platform technology.

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Variants of SARS-CoV-2, COVID-19 pandemic in India, SARS-CoV-2 Delta variant, COVID-19, Variant, Delta, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

MENLO PARK, Calif. and AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (“mAb”) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.

Key Points: 
  • The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.
  • The Delta variant now accounts for 83% of new cases in the U.S., according to recent CDC data.
  • Demonstration that AUG-3387 effectively neutralizes the Delta variant in vitro is an encouraging step towards developing the therapy to slow and prevent ongoing spread of COVID-19.
  • Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially.

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Coronaviridae, Medicine, Health sciences, Zoonoses, COVID-19 vaccines, Sarbecovirus, Bat virome, Clinical trials, COVID-19 vaccine, Severe acute respiratory syndrome, Coronavirus, COVID-19

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir

Retrieved on: 
Wednesday, July 28, 2021
Biology, 3C-like protease, Sarbecovirus, Protease inhibitor, Antiviral drug, Protease, Biomarker, Branches of biology, 3CLpro-1

New York, NY, and Tel Aviv, ISRAEL, July 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has retained the services of Innvocept Global Solutions, an Indian clinical research organization (CRO), to manage 2 adaptive design Phase 2/3 clinical trials the Company is preparing to initiate with its joint venture partner NLC Pharma of its proprietary oral antiviral 3CL protease inhibitor drug candidate Tollovir™ for the treatment of non-hospitalized and hospitalized COVID-19 patients in India. Engaging a CRO is the first step of the regulatory process in India.  The Company expects enrollment for both trials to begin in the third quarter of 2021 with initial, trial expansion-enabling data expected in the fourth quarter of 2021 that could make each trial become part of the Company’s global pivotal clinical development program for Tollovir that would begin in the fourth quarter of 2021.

Key Points: 
  • This trial opened enrollment in April 2021 and is also evaluating the use of TolloTest as a companion diagnostic for antiviral therapy.
  • TolloTest is the Companys proprietary 3CL protease biomarker assay that is being developed as a more accurate measure of viral infection, load and infectiousness in COVID-19 patients.
  • This dual mechanism makes Tollovir unique among the emerging class of 3CL protease inhibitors currently in development.
  • For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials.